In vitro antiviral activity of a peptide-nucleic acid solution against the human immunodeficiency virus and influenza A virus.
A peptide-nucleic acid solution which had previously been reported to show in vivo efficacy in several viral infections (i.e. influenza, hepatitis, mumps, encephalitis, etc) was tested in three independent laboratories, including the US National Institutes of Health by specific in vitro methods for HIV and Influenza A. The results of these studies demonstrated significant anti-viral activity of the peptide-nucleic acid solution against the Human Immunodeficiency Virus (HIV) and the Influenza A virus.
Friedland
B
B
D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D015726:Giant Cells / Q000187:drug effects; D016655:HIV Core Protein p24 / Q000187:drug effects; D015497:HIV-1 / Q000187:drug effects*; D009980:Influenza A virus / Q000187:drug effects*; D008074:Lipoproteins / Q000494:pharmacology*; D016399:Lymphoma, T-Cell; D009696:Nucleic Acids / Q000494:pharmacology*; D020135:Peptide Nucleic Acids; D010455:Peptides / Q000494:pharmacology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma; D012194:RNA-Directed DNA Polymerase / Q000187:drug effects; D014776:Virus Cultivation
D000998:Antiviral Agents; D016655:HIV Core Protein p24; D008074:Lipoproteins; D009696:Nucleic Acids; D020135:Peptide Nucleic Acids; D010455:Peptides; D012194:RNA-Directed DNA Polymerase